ORAGENICS INC
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
OGEN$0.35+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
| Common Stock · Preferred Stock · Additional Paid In · Accumulated · Total Shareholders’ | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Deficit | Equity | |
| Balances at December 31, 2022 | 2,024,657 | $2,025 | 9,467,000 | $1,592,723 | $196,977,071 | $(185,562,517) | $13,009,302 |
| Compensation expense relating to option issuances | — | — | — | — | 550,083 | — | 550,083 |
| Compensation expense relating to restricted stock issuances | 140,000 | 140 | — | — | 466,605 | — | 466,745 |
| Issuance of Series F preferred stock | 8,000,000 | — | 8,947,834 | — | 8,947,834 | ||
| Conversion of Series F preferred stock to common stock | 511,308 | 511 | (511,803) | — | (511) | — | — |
| Common stock issued in private placement | 404,728 | 405 | — | — | 849,522 | — | 849,927 |
| Net loss | — | — | — | — | — | (20,655,737) | (20,655,737) |
| Balances at December 31, 2023 | 3,080,693 | $3,081 | 16,955,197 | $1,592,723 | $207,790,604 | $(206,218,254) | $3,168,154 |
| Common Stock · Preferred Stock · Additional Paid In · Accumulated · Total Shareholders’ | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Deficit | Equity | |
| Balances at December 31, 2021 | 2,002,946 | $2,003 | 16,017,000 | $2,656,713 | $195,101,611 | $(171,274,128) | $26,486,199 |
| Compensation expense relating to option issuances | — | — | — | — | 742,203 | — | 742,203 |
| Conversion of Series A preferred stock to common stock | 6,667 | 7 | (4,000,000) | (415,169) | 415,162 | — | — |
| Conversion of Series B preferred stock to common stock | 8,500 | 9 | (2,550,000) | (648,821) | 648,812 | — | — |
| Proceeds from issuance of common stock | 6,544 | 6 | 69,283 | 69,289 | |||
| Net loss | — | — | — | — | — | (14,288,389) | (14,288,389) |
| Balances at December 31, 2022 | 2,024,657 | $2,025 | 9,467,000 | $1,592,723 | $196,977,071 | (185,562,517) | $13,009,302 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.